JGC
COGT icon

J. Goldman & Co’s Cogent Biosciences COGT Stock Holding History

J. Goldman & Co’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30M Buy
779,570
+340,301
+77% +$12.6M 0.87% 11
2025
Q4 		$15.6M Buy
+439,269
New +$12.3M 0.41% 63

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

J. Goldman & Co's COGT Position: Q1 2026 in Review

J. Goldman & Co increased its Cogent Biosciences (COGT) stake by 77% in Q1 2026, buying an estimated $12.6M and bringing the position to 779,570 shares worth $30M. The position accounts for 0.87% of the portfolio, ranked #11.

J. Goldman & Co first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • J. Goldman & Co held 779,570 shares of Cogent Biosciences worth $30M as of Q1 2026.
  • J. Goldman & Co bought 340,301 Cogent Biosciences shares in Q1 2026, an estimated $12.6M.
  • Cogent Biosciences made up 0.87% of J. Goldman & Co's portfolio in Q1 2026, its #11 holding.
  • J. Goldman & Co first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.